Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
Wall Street Beats to Host Conference Call with Sarepta CEO on Ground-Breaking Expanded Label Approval
01:21pm, Friday, 21'st Jun 2024
SAN DIEGO--(BUSINESS WIRE)--Wall Street Beats is pleased to announce an investor conference call with Doug Ingram, CEO of Sarepta Therapeutics, following the landmark FDA approval expanding the label
Sarepta Stock Surges On FDA News; Industrial Stock In Buy Zone
12:29pm, Friday, 21'st Jun 2024
This biotech stock surged after one of its gene therapies was approved by the Food and Drug Administration.
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
12:25pm, Friday, 21'st Jun 2024
Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
Sarepta (SRPT) Soars on FDA Approval on Muscular Dystrophy Treatment
12:14pm, Friday, 21'st Jun 2024
Sarepta (SRPT) soars after the FDA approves expanded use of their Muscular Dystrophy treatment. Jenny Horne weighs in on this story.
Sarepta Therapeutics Stock Soars on FDA Approval
12:06pm, Friday, 21'st Jun 2024
Sarepta Therapeutics NASDAQ: SRPT is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving expanded FDA
Sarepta Soars on Expanded Approval for Muscular Dystrophy Drug
10:10am, Friday, 21'st Jun 2024
Sarepta Therapeutics' gene therapy received expanded US approval to include more children with a deadly muscle disease. The treatment's approval was widened for use in patients who are at least 4 year
Sarepta Therapeutics shares surge as muscular dystrophy therapy approved for expanded use
10:05am, Friday, 21'st Jun 2024
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares soared almost 35% after the US Food and Drug Administration (FDA) approved the expanded use of its gene therapy Elevidys for patients with Duchenne muscul
Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost
09:32am, Friday, 21'st Jun 2024
Sarepta Therapeutics (NASDAQ: SRPT ) stock jumped about 30% overnight after the Food and Drug Administration (FDA) approved one of its gene therapies for children with Duchenne muscular dystrophy (DMD
Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug
09:31am, Friday, 21'st Jun 2024
Sarepta Therapeutics (SRPT) shares soared in premarket trading Friday, a day after the Food and Drug Administration (FDA) allowed expanded use of the biotech's treatment for a rare muscle disease in c
Sarepta Therapeutics' stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug
08:05am, Friday, 21'st Jun 2024
Sarepeta Therapeutics Inc.'s stock soared 38% in premarket trade Friday, after the biotech said the U.S. regulator has approved an expanded indication of its treatment for the rare muscle disorder Duc
Sarepta Stock Surges on Expanded Approval for Elevidys. What Wall Street Thinks.
07:43am, Friday, 21'st Jun 2024
The biopharmaceutical company says the drug was approved for ambulatory and non-ambulatory people, who are at least 4 years old, and with a confirmed mutation in the DMD gene.
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
07:39am, Friday, 21'st Jun 2024
Thursday, the FDA approved labeled indication for Sarepta Therapeutics Inc's SRPT Elevidys (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a conf
Sarepta surges as investors cheer expanded use of gene therapy
06:53am, Friday, 21'st Jun 2024
Sarepta Therapeutics shares surged about 36% in premarket trading on Friday as an expanded use approval opened up a bigger market in the U.S. for its gene therapy for patients with Duchenne muscular d
Why has the Sarepta stock price (SRPT) gone up more than 35%?
05:12am, Friday, 21'st Jun 2024
Sarepta Therapeutics (NASDAQ: SRPT), a pharmaceutical company that describes itself as specializing in “precision genetic medicine for rare diseases”, saw its stock price shoot up by 36% in after-
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
08:30pm, Thursday, 20'th Jun 2024
Sarepta rocketed late Thursday after the FDA approved its Duchenne muscular dystrophy gene therapy for all patients age 4 and older.
